Rare Eye Tumors: When Leukemia Shows Up in the Eyelid
"An unusual case highlights the importance of considering leukemia in the diagnosis of eyelid and conjunctival masses, even without typical blood abnormalities."
Leukemia, a cancer of the blood-forming tissues, can manifest in surprising ways. While often associated with systemic symptoms and abnormalities in blood counts, a recent case highlights a rare presentation: tumors in the eyelid and conjunctiva as the first sign of acute myeloid leukemia (AML).
AML, a type of cancer affecting the bone marrow and blood, can sometimes lead to the development of myeloid sarcoma, also known as granulocytic sarcoma or chloroma. This occurs when leukemic cells infiltrate tissues outside the bone marrow. These infiltrations can occur nearly anywhere in the body.
A recent case report underscores the importance of considering leukemia in the differential diagnosis of eyelid and conjunctival masses, even when initial blood tests appear normal. This article explores this unusual presentation of AML, drawing from a detailed case study.
AML Statistics and Data
The SEER Cancer Stat Facts page says its acute myeloid leukemia statistics are based on data from SEER and the CDC’s National Center for Health Statistics, with most available through SEER*Explorer. The American Cancer Society’s key-statistics page provides its latest estimates for AML in the United States. Separately, The World Data reports that AML accounted for 47.1% of U.S. leukemia deaths while representing 32.9% of cases in its 2026 figures. These sources describe different statistical resources and measures, so the figures should be read in their stated contexts.
The Case: Atypical Presentation of AML
The case involved an 82-year-old man who presented with bilateral conjunctival masses and a mass on his right eyelid. He had a history of prostate cancer treated with chemotherapy and stroke managed with carotid artery stent placement and medication.
- Neutrophils: 74.4%
- Lymphocytes: 10%
- Monocytes: 11.8%
Research on Eyelid Myeloid Sarcoma
A report titled “Eyelid myeloid sarcoma heralding relapse of acute myeloid leukemia in a child: First report from India and literature review” describes a child who developed a small nodule below the right eyelid on day 10 of first consolidation chemotherapy with high-dose cytarabine. A separate review describes changes in AML diagnosis, risk assessment, monitoring, and treatment over the last decade, attributing them to increased understanding of the disease and improved assessment technology. That review also notes the addition of at least 12 approved therapies. Together, these sources place a rare eyelid presentation alongside broader changes in AML research and care.
Unusual Eye Findings Need Investigation
A report on an orbital lesion recommends aggressive work-up when an unusual lesion has no explainable cause, and says AML should be considered even when systemic leukemia manifestations are absent. A separate overview describes ocular involvement as potentially the first sign of leukemia, a relapse, or systemic progression. A 2025 clinical course also says acute retinal vascular changes associated with AML should prompt further work-up. These sources support attention to atypical ocular findings, while not establishing that such findings alone diagnose AML.
Different Leukemia Types in Historical Reports
A histopathologic study of 42 leukemia cutis cases reported three patients with acute lymphocytic leukemia, 16 with chronic lymphocytic leukemia, 12 with acute granulocytic leukemia, three with chronic granulocytic leukemia, five with acute monocytic leukemia, and three with acute myelomonocytic leukemia. A separate report on aclarubicin treatment in elderly patients with acute nonlymphocytic leukemia reported a complete-remission rate of 83% among six patients with acute myelomonocytic or acute monocytic leukemia. The studies address different questions and populations: one describes diagnoses among leukemia cutis cases, while the other reports treatment outcomes in a small group. Their figures therefore do not constitute a direct comparison of eyelid tumors or treatment effectiveness across leukemia subtypes.
Key Takeaways and Clinical Implications
This case underscores the importance of considering systemic conditions like leukemia when evaluating eyelid and conjunctival masses. Even in the absence of typical blood abnormalities, a high index of suspicion is warranted.
Targeted AML Therapies and Market Outlook
A 2025 review says advances in molecular profiling have improved understanding of genetic and epigenetic alterations driving AML and revealed novel therapeutic targets; it describes targeted molecular and epigenetic treatments as increasingly important. Mordor Intelligence estimates the AML therapeutics market at USD 2.88 billion in 2025 and projects growth from USD 3.18 billion in 2026 to USD 5.18 billion by 2031, with a forecast-period CAGR of 10.29%. These market figures are projections, not clinical outcome data. A separate 2026 article states that AML incidence is 6.6 cases per 100,000 people per year and is slightly more common in men.
Eyelid Masses in Individual AML Cases
A 2019 case report describes eyelid myeloid sarcoma that mimicked pre-septal cellulitis and presented as a sign of AML without systemic symptoms; the patient had a history of lymphadenopathy for several months. Another report describes an 80-year-old woman who developed a firm, pinkish mass on the left upper eyelid margin during AML chemotherapy. Although no blast cells were found in her peripheral blood at biopsy, the leukemia recurred, and the patient died. A separate 2014 report characterized eyelid myeloid sarcoma as the presenting sign of AML and described the lesion’s prognosis as poor.
While myeloid sarcoma is relatively rare, it should be included in the differential diagnosis of atypical eyelid and conjunctival lesions, especially in older adults with a history of cancer or other predisposing factors.
Further research is needed to better understand the pathogenesis and optimal management of myeloid sarcoma presenting in unusual locations. Early recognition and prompt treatment are crucial for improving patient outcomes.